Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in Chinese patients with primary hypercholesterolemia (HUA TUO)
NCT03433755Phase 3Terminated
- Sponsor
- Amgen
- Start
- May 2019
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab in hypercholesterolemia, mixed dyslipidemia, sponsored by Amgen. Started May 2019; status: terminated.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT03433755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03433755.